Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: AbbVie

Humira revenues up 11% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie
 
4Q Revenues: $6.4 billion (+17%)

4Q Earnings: $1.5 billion (loss of $810 million 4Q14)

FY Revenues: $22.9 billion (+15%)

FY Earnings: $5.1 billion (+190%)

Comments: Humira revenues were $3.7 billion in the quarter, up 11%. Growth in the quarter was also driven by Imbruvica sales of $343 million, Viekira sales of $554 million, and Creon sales of $185 million. Lupron sales were $235 million, up 13%. Synagis sales were down 11% to $266 million. Kaletra sales were down 9% to $185 million. AndroGel sales were down 16% to $194 million. 2014 earnings were impacted by the Shire termination.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters